Foghorn Therapeutics Valuation
| FHTX Stock | USD 4.05 0.07 1.70% |
At this time, the firm appears to be overvalued. Foghorn Therapeutics shows a prevailing Real Value of $3.83 per share. The current price of the firm is $4.05. Our model computes the value of Foghorn Therapeutics from reviewing the firm fundamentals such as Operating Margin of (8.41) %, shares owned by insiders of 18.97 %, and Shares Outstanding of 55.61 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Foghorn Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Foghorn Therapeutics is based on 3 months time horizon. Increasing Foghorn Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Foghorn Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Foghorn Stock. However, Foghorn Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.05 | Real 3.83 | Hype 4.05 | Naive 4.72 |
The intrinsic value of Foghorn Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Foghorn Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Foghorn Therapeutics helps investors to forecast how Foghorn stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Foghorn Therapeutics more accurately as focusing exclusively on Foghorn Therapeutics' fundamentals will not take into account other important factors: Foghorn Therapeutics Total Value Analysis
Foghorn Therapeutics is currently anticipated to have valuation of 18.06 M with market capitalization of 229.69 M, debt of 37.13 M, and cash on hands of 373.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Foghorn Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
18.06 M | 229.69 M | 37.13 M | 373.5 M |
Foghorn Therapeutics Investor Information
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.55. Foghorn Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Foghorn Therapeutics' liquidity, profitability, solvency, and operating efficiency, Foghorn Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Foghorn Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Foghorn Therapeutics has an asset utilization ratio of 7.96 percent. This suggests that the Company is making $0.0796 for each dollar of assets. An increasing asset utilization means that Foghorn Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Foghorn Therapeutics Ownership Allocation
Foghorn Therapeutics holds a total of 55.61 Million outstanding shares. The majority of Foghorn Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Foghorn Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Foghorn Therapeutics. Please pay attention to any change in the institutional holdings of Foghorn Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Foghorn Therapeutics Profitability Analysis
The company reported the previous year's revenue of 22.6 M. Net Loss for the year was (86.62 M) with loss before overhead, payroll, taxes, and interest of (71.93 M).About Foghorn Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Foghorn Therapeutics. We calculate exposure to Foghorn Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Foghorn Therapeutics's related companies.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
Foghorn Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 54.9 M |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.